1 published article · Updated continuously
10 trials tracked for Anterior uveitis: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 18 citations.
Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Suprachoriodal administration of 4mg CLS-TA has demonstrated significant clinical improvements in patients with anterior uveitis. Specifically, it resulted in a statistically significant number of subjects achieving at least a 15-letter improvement from baseline in best corrected visual acuity at 24 weeks (p<0.001) 2.
Clinical markers of inflammation and haze associated with CLS-TA suprachoriodal injection show high rates of resolution. Patients treated with 4mg CLS-TA demonstrated a Grade of 0 in anterior chamber flare (34/38), anterior chamber cells (31/38), and vitreous haze (34/38) 3. Additionally, H.P. ACTHAR subcutaneous gel injection was associated with the reduction of photographic haze to Grade 0 or down by two steps 1.
The use of 4mg CLS-TA suprachoriodal injection did not show a statistically significant difference in the time to additional therapy for uveitis compared to the control group (p=0.562) 8.
AI synthesis of 7 cited trials, updated Jul 8, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
